Other Events ·
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized…
MNMDMind Medicine (MindMed) Inc.
Definium Therapeutics announced positive topline results from its Phase 3 Voyage study of DT120 ODT for generalized anxiety disorder. The trial met all primary and key secondary efficacy endpoints, demonstrating a statistically significant placebo-adjusted reduction in Hamilton Anxiety Rating Scale (HAM-A) scores of 5.4 points at Week 12 (p<0.0001). The drug was generally well tolerated with no new safety signals identified. Definium Therapeutics is a late-stage clinical biopharmaceutical company developing psychedelic-inspired therapeutics for psychiatric and neurological disorders.